Discovery and Preliminary Characterization of Translational Modulators that Impair the Binding of eIF6 to 60S Ribosomal Subunits.
Cell Line
Cell Nucleolus
/ drug effects
Cell Survival
Enzyme-Linked Immunosorbent Assay
Humans
Peptide Chain Initiation, Translational
/ drug effects
Peptide Initiation Factors
/ metabolism
Polyribosomes
/ drug effects
Protein Binding
/ drug effects
Protein Biosynthesis
Puromycin
/ pharmacology
RNA, Messenger
/ genetics
Reproducibility of Results
Ribosome Subunits, Large, Eukaryotic
/ metabolism
RACK1
Shwachman–Diamond syndrome
eIF4E
eIFsixty-i
iRIA
initiation
polysomes
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
10 01 2020
10 01 2020
Historique:
received:
26
11
2019
revised:
07
01
2020
accepted:
08
01
2020
entrez:
16
1
2020
pubmed:
16
1
2020
medline:
16
1
2021
Statut:
epublish
Résumé
Eukaryotic initiation factor 6 (eIF6) is necessary for the nucleolar biogenesis of 60S ribosomes. However, most of eIF6 resides in the cytoplasm, where it acts as an initiation factor. eIF6 is necessary for maximal protein synthesis downstream of growth factor stimulation. eIF6 is an antiassociation factor that binds 60S subunits, in turn preventing premature 40S joining and thus the formation of inactive 80S subunits. It is widely thought that eIF6 antiassociation activity is critical for its function. Here, we exploited and improved our assay for eIF6 binding to ribosomes (iRIA) in order to screen for modulators of eIF6 binding to the 60S. Three compounds, eIFsixty-1 (clofazimine), eIFsixty-4, and eIFsixty-6 were identified and characterized. All three inhibit the binding of eIF6 to the 60S in the micromolar range. eIFsixty-4 robustly inhibits cell growth, whereas eIFsixty-1 and eIFsixty-6 might have dose- and cell-specific effects. Puromycin labeling shows that eIF6ixty-4 is a strong global translational inhibitor, whereas the other two are mild modulators. Polysome profiling and RT-qPCR show that all three inhibitors reduce the specific translation of well-known eIF6 targets. In contrast, none of them affect the nucleolar localization of eIF6. These data provide proof of principle that the generation of eIF6 translational modulators is feasible.
Identifiants
pubmed: 31936702
pii: cells9010172
doi: 10.3390/cells9010172
pmc: PMC7017188
pii:
doi:
Substances chimiques
Peptide Initiation Factors
0
RNA, Messenger
0
eIF-6
0
Puromycin
4A6ZS6Q2CL
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
J Biomol Screen. 1999;4(2):67-73
pubmed: 10838414
Cold Spring Harb Perspect Biol. 2019 Sep 3;11(9):
pubmed: 29959195
Eur J Cancer. 2018 Sep;101:165-180
pubmed: 30077122
J Thromb Haemost. 2015 Nov;13(11):2108-18
pubmed: 26391622
Elife. 2013 May 28;2:e00498
pubmed: 23741617
Blood. 2016 Jul 21;128(3):410-4
pubmed: 27307295
Dev Comp Immunol. 2017 Dec;77:69-76
pubmed: 28743432
Mol Cell Biol. 2018 May 29;38(12):
pubmed: 29610153
PLoS Genet. 2017 Jan 5;13(1):e1006552
pubmed: 28056084
Science. 2010 May 28;328(5982):1172-6
pubmed: 20508131
Nat Med. 2019 Feb;25(2):301-311
pubmed: 30643286
Mol Cell. 2010 Jul 30;39(2):196-208
pubmed: 20670889
Biochim Biophys Acta. 2015 Jul;1849(7):830-5
pubmed: 25252159
Nature. 2003 Dec 4;426(6966):579-84
pubmed: 14654845
Nature. 2013 Jan 17;493(7432):411-5
pubmed: 23263185
Blood. 2011 Oct 20;118(16):4305-12
pubmed: 21803848
Oncotarget. 2015 Nov 10;6(35):37471-85
pubmed: 26462016
J Cell Biol. 1999 Mar 8;144(5):823-37
pubmed: 10085284
Nature. 2008 Oct 2;455(7213):684-8
pubmed: 18784653
J Biol Chem. 1998 Apr 17;273(16):9373-7
pubmed: 9545260
Science. 2011 Nov 18;334(6058):941-8
pubmed: 22052974
Biomed Res Int. 2016;2016:7086390
pubmed: 27872854
J Clin Invest. 2010 Aug;120(8):2858-66
pubmed: 20664172
Assay Drug Dev Technol. 2009 Feb;7(1):90-2
pubmed: 19382891
Blood Cells Mol Dis. 2006 Jan-Feb;36(1):26-32
pubmed: 16380275
Cell. 2009 Feb 20;136(4):731-45
pubmed: 19239892
J Biol Chem. 1979 Sep 25;254(18):8796-800
pubmed: 479160
Curr Opin Genet Dev. 2018 Feb;48:75-81
pubmed: 29153483
Nat Genet. 2014 Oct;46(10):1051-9
pubmed: 25151356
Nat Rev Cancer. 2016 Apr 26;16(5):288-304
pubmed: 27112207
Nat Genet. 2003 Jan;33(1):97-101
pubmed: 12496757
Nat Rev Drug Discov. 2015 Apr;14(4):261-78
pubmed: 25743081
Genes Dev. 2011 May 1;25(9):917-29
pubmed: 21536732
Nat Commun. 2015 Sep 18;6:8261
pubmed: 26383020
Oncogene. 2014 Apr 24;33(17):2145-56
pubmed: 23644661
Cancer Res. 2000 Feb 1;60(3):510-6
pubmed: 10676626
Biochem Soc Trans. 2016 Dec 15;44(6):1667-1673
pubmed: 27913676
Curr Opin Genet Dev. 2018 Feb;48:82-88
pubmed: 29153484
Cell Chem Biol. 2019 Nov 21;26(11):1586-1593.e3
pubmed: 31519508
Sci Rep. 2015 Oct 21;5:15401
pubmed: 26486184
Mol Cell. 2001 Dec;8(6):1363-73
pubmed: 11779510
Science. 2016 Jun 17;352(6292):1413-6
pubmed: 27313038
Science. 2018 Mar 30;359(6383):1533-1536
pubmed: 29599245
Trends Biochem Sci. 2001 Apr;26(4):225-9
pubmed: 11295554
Genes Dev. 2007 Dec 15;21(24):3232-7
pubmed: 18055695
J Histochem Cytochem. 1992 Apr;40(4):535-40
pubmed: 1552187
Cell Metab. 2018 Dec 4;28(6):895-906.e5
pubmed: 30197303
Cancer Cell. 2010 Mar 16;17(3):249-61
pubmed: 20227039
Cell Cycle. 2011 Oct 15;10(20):3441-6
pubmed: 22031223
Elife. 2019 May 22;8:
pubmed: 31115337
Nat Genet. 2007 Apr;39(4):486-95
pubmed: 17353896
EMBO Rep. 2009 May;10(5):459-65
pubmed: 19373251
J Biol Chem. 1997 Nov 28;272(48):30314-21
pubmed: 9374518
Nat Struct Mol Biol. 2015 Nov;22(11):914-9
pubmed: 26479198
J Clin Invest. 2016 Jun 1;126(6):2181-90
pubmed: 27159396